November 18, 2017New England Journal of Medicine5,447 citationsOpen Access
Osimertinib in Untreated EGFR -Mutated Advanced Non–Small-Cell Lung Cancer
View Full Paper
Key Points
Key points are not available for this paper at this time.
Abstract
Osimertinib showed efficacy superior to that of standard EGFR-TKIs in the first-line treatment of EGFR mutation-positive advanced NSCLC, with a similar safety profile and lower rates of serious adverse events. (Funded by AstraZeneca; FLAURA ClinicalTrials.gov number, NCT02296125 .).
Cite This Study
Soria et al. (2017) studied this question.